Perlegen
-
Genetic Technologies Acquires Beast Cancer Risk Test
Genetic Technologies has acquired certain assets from US-based Perlegen Sciences, with the main asset being the BrevaGen breast cancer risk test. In addition to the test, GTG has acquired a suite of granted patents that are valid to 2022 which augmen…
Perlegen | 19 April 2010
